ISCO’s scientists presented pre-clinical research results at the International Society for Stem Cell Research 10th Annual Meeting

International Stem Cell Corporation’s (www.internationalstemcell.com) scientists presented pre-clinical research results at the International Society for Stem Cell Research (ISSCR) 10th Annual Meeting. This is the first time the ISSCR meeting has been held in Asia (Yokohama, Japan). The Emperor and Empress of Japan even made a guest appearance at the Conference.

Our scientists presented the latest advancements in our Parkinson’s disease therapeutic program. We have derived A9 dopaminergic neurons from human parthenogenetic stem cells (hpSC) and demonstrated that these neurons engraft, survive in vivo, and release dopamine in an animal (rat) model of Parkinson’s disease.

We also presented the most recent data on the in vitro and in vivo characterization of hpSC-derived hepatocytes generated as a treatment for multiple liver disorders. These advancements represent an important milestone in our regenerative medicine program and bring us closer to be able to treat individuals suffering from various liver diseases.

I think the Conference went well for us, as it exposed our research to some well-known stem cell scientists and their feedback was both positive and, more importantly, useful to us.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and new manufacturing technologies, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and technologies regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

ISCO Scientists Create New Protein-Based Stem Cell Technology

CARLSBAD, Calif. June 14, 2012- International Stem Cell Corporation (OTCBB: ISCO) www.internationalstemcell.com announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs".  TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products. 

In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells.  In addition, the TTF proteins are naturally eliminated by the cells when no longer required, a characteristic that further improves safety.  The Company intends that this technology, once perfected, will first be used to create revenue-generating research products for sale through Lifeline Cell Technology’s international distribution channels to the academic, biotechnology and pharmaceutical markets for cellular proteins, including the quickly growing markets for the study of stem cell biology and drug testing. 

According to Jeffrey Janus, Lifeline Cell Technology’s CEO, “These proteins can be sold into the market for cellular proteins which exceeds $700 million and represents an excellent opportunity for LCT to grow sales.  Since the technology also has broad application in research and therapy, it should provide ISCO with future out-licensing opportunities to the biotechnology and pharmaceutical industries.”

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. 

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0